ESSA Pharma Inc. Files 8-K

TL;DR

ESSA Pharma filed an 8-K on Oct 3rd covering votes and other events. Check it out.

AI Summary

ESSA Pharma Inc. filed an 8-K on October 6, 2025, reporting on matters submitted to a vote of security holders and other events. The filing also includes financial statements and exhibits. The report date for the earliest event is October 3, 2025.

Why It Matters

This 8-K filing provides updates on ESSA Pharma Inc.'s corporate actions, including votes by security holders and other significant events, which are crucial for investors to understand the company's governance and operational status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain immediate material risks.

Key Players & Entities

• ESSA Pharma Inc. (company) — Registrant
• October 3, 2025 (date) — Earliest event reported
• October 6, 2025 (date) — Date of report

FAQ

Filing Documents

• tm2527983d1_8k.htm (8-K) — 56KB
• tm2527983d1_ex99-1.htm (EX-99.1) — 14KB
• 0001104659-25-097168.txt ( ) — 245KB
• epix-20251003.xsd (EX-101.SCH) — 3KB
• epix-20251003_lab.xml (EX-101.LAB) — 33KB
• epix-20251003_pre.xml (EX-101.PRE) — 22KB
• tm2527983d1_8k_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 3, 2025, ESSA Pharma Inc. (the " Company ") convened a special meeting (the " Meeting ") of the holders of the Company's common shares (the " Common Shares ", and the holders of such Common Shares, the " Shareholders "), the holders of stock options of the Company (the " Options ", and the holders of such Options, the " Optionholders ") and the holders of pre-funded Common Share purchase warrants of the Company (the " Warrants ", and the holders of such Warrants, the " Warrantholders " and, together with the Shareholders and the Optionholders, the " Securityholders "). At the Meeting, the Securityholders were asked to consider and, if thought advisable, to pass, with or without variation, a special resolution (the " Arrangement Resolution "), to approve an arrangement (the " Arrangement ") under Section 288 of the Business Corporations Act (British Columbia) involving the Company, XenoTherapeutics, Inc., Xeno Acquisition Corp., and, solely for the limited purpose stated therein, XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025 and the plan of arrangement. In addition, Shareholders were asked to consider and, if thought advisable, to pass, with or without variation (i) an ordinary resolution to approve, on an advisory and non-binding basis, the compensation to be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Arrangement (the " Compensation Resolution "); and (ii) in the event that the Arrangement Resolution is not approved or the Arrangement is otherwise terminated, (1) a special resolution pursuant to Section 319(1) of the BCBCA to approve the voluntary liquidation and dissolution of the Company (the " Liquidation Resolution "), and (2) an ordinary resolution pursuant to Section 319(2) of the BCBCA to approve the appointment of PricewaterhouseCoopers LLP or, in the alternative, another

01 Other Events

Item 8.01 Other Events. On October 6, 2025, the Company issued a press release containing information about the voting results of the Meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated October 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward Looking Statements

Forward Looking Statements This communication, and any related oral statements, contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, " forward-looking statements "). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate," "believe," "plan," "estimate," "expect," and "intend," statements that an action or event "may," "might," "could," "should," or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction, and other statements that are not statements of historical facts. In this communication, these forward-looking expected date of closing of the Transaction and the potential benefits thereof, the Company's business and industry, management's beliefs and certain assumptions made by the Company, all of which are subject to change. Forward-looking control or predict, and which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. Such necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the date of

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESSA PHARMA INC. (Registrant) Date: October 6, 2025 By: /s/ David Wood Name: David Wood Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR